DZ-837
DZ-837 (compound 3d) is a PROTAC targeting BCL6 with a DC50 of approximately 600 nM. DZ-837 can induce cell cycle arrest and exert synergistic anticancer effects with Ibrutinib. DZ-837 is composed of PROTAC target protein ligand BCL6 ligand-2 (HY-161990) (red part), E3 ubiquitin ligase ligand Thalidomide-4-OH (HY-103596) (blue part), and PROTAC Linker (HY-W245803) (black part), among which the conjugate of E3 ubiquitin ligase ligand + Linker is 2- (2,6-Dioxopiperidin-3-yl) -4- ((2- (2-hydroxyethoxy) ethyl) amino) isoindoline-1,3-dione (HY-W924949).
Product Specifications
UNSPSC
12352005
Target
BCL6; PROTACs
Type
Reference compound
Related Pathways
Immunology/Inflammation; PROTAC
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/dz-837.html
Purity
96.04
Solubility
DMSO : 25 mg/mL (ultrasonic; heat to 60°C)
Smiles
O=C(C1=CC=C(C2=CCCC2)S1)NC3=CC=C(NC4=NC(N5CCN(CCOCCNC6=CC=CC(C(N7C(CC8)C(NC8=O)=O)=O)=C6C7=O)CC5)=NC=C4F)C=C3OC
Molecular Formula
C42H44FN9O7S
Molecular Weight
837.92
References & Citations
Shipping Conditions
Blue Ice
Storage Conditions
-20°C, 3 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Thyroglobulin (6E1.), CF568 conjugate, 0.1mg/mL
COX8A CRISPRa sgRNA lentivector (set of three targets)(Rat)